Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fezagepras - Liminal BioSciences

Drug Profile

Fezagepras - Liminal BioSciences

Alternative Names: PBI 4050; Setogepram - Liminal BioSciences

Latest Information Update: 15 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ProMetic Life Sciences
  • Developer Liminal BioSciences; ProMetic Life Sciences
  • Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Hepatoprotectants; Phenylacetates; Skin disorder therapies; Small molecules
  • Mechanism of Action AMP activated protein kinase modulators; Autophagy stimulants; Cell differentiation modulators; Colony stimulating factor stimulants; Cytokine modulators; Erythropoiesis stimulants; Extracellular matrix protein inhibitors; FFAR1 protein modulators; GPR84 protein antagonists; Immunomodulators; Inflammation mediator inhibitors; MTOR protein inhibitors; MTOR protein modulators; PPAR alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn genetic disorders; Idiopathic pulmonary fibrosis; Alstrom's Syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Alstrom's Syndrome
  • Phase II Cystic fibrosis; Diabetic nephropathies; Idiopathic pulmonary fibrosis; Metabolic syndrome; Scleroderma; Type 2 diabetes mellitus
  • Preclinical Acute lung injury; Liver disorders; Pulmonary hypertension
  • No development reported Anaemia; Haematological disorders; Neutropenia; Renal fibrosis

Most Recent Events

  • 13 Jan 2020 Liminal BioSciences plans preclinical studies and two phase II studies for respiratory diseases in USA and Europe
  • 13 Jan 2020 Liminal BioSciences plans a phase III trial for Alstrom's syndrome in USA and European Union in second half of 2020
  • 28 Dec 2019 No recent reports of development identified for preclinical development in Renal-fibrosis in Canada (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top